Phase 2 trial ancillary study reports innate and cellular immune responses to Ad26.ZEBOV and MVA-BN-Filo in European adults, highlighting broader mechanisms of authorized Ebola vaccination.
The EBL2001 phase 2 trial tested the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to EU market authorization in 2020. Complementary analyses of immune responses are warranted to better characterize vaccine effects.
No takes yet. Share an insight, caveat, or question.
Lacabaratz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: